Skip to main
IGC

IGC Stock Forecast & Price Target

IGC Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

IGC Pharma is supported by a compelling Alzheimer’s pipeline, led by IGC-AD1, which has shown promise in cell lines against plaques and tangles and produced clinically and statistically significant agitation reduction versus placebo in a March 2024 interim analysis. The investment case is strengthened by execution progress, with 100% enrollment of the 146-patient Phase 2 CALMA trial achieved in August and the company now within 6 additional randomizations of closure, while earlier April updates showed over 80% enrollment. With two major milestones expected in 2026, an attractive NPV-based valuation, and a billion-dollar market opportunity, the stock offers substantial upside if positive data continue to validate the program.

Bears say

IGC Pharma is an early/clinical-stage biotech with minimal revenue, posting just $0.3 million in both fiscal Q1 2026 and fiscal Q2 2026, while losses widened to $2.4 million and $2.9 million, respectively, underscoring a persistently weak earnings profile. Its Alzheimer’s pipeline may address a large unmet need, but the company remains dependent on unproven product candidates such as IGC-AD1, IGC-M3, IGC-1C, and TGR-63 to demonstrate safety, efficacy, and regulatory viability before any meaningful commercialization can occur. Balance sheet and liquidity risk, reimbursement uncertainty, and competitive and macroeconomic pressures further limit conviction, especially given the limited and transient effects of currently available Alzheimer’s drugs.

IGC has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of India Globalization Capital and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About India Globalization Capital (IGC) Forecast

Analysts have given IGC a Strong Buy based on their latest research and market trends.

According to 1 analysts, IGC has a Strong Buy consensus rating as of Oct 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

India Globalization Capital (IGC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.